These bills generally establish state requirements for pharmacists to dispense an “interchangeable biologic” medicine as a substitute for an earlier-approved biologic. Requirements vary in individual states.
These measures generally use state law to seek a path for terminally ill patients to obtain legal access to try experimental drugs not yet approved by the FDA. In the past 18 months, 24 such bills have become law.

For information contact NCSL Pharmaceuticals Project staff:
Richard Cauchi, Program Director; Ashley Noble, Policy Associate, NCSL Health Program - Denver